Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine

Biomedicine and Pharmacotherapy

Volumn 63, Issue 9, 2009, Pages 697-702

  Dorababu, Madhura ^a,b   Nishimura, Asako ^b   Prabha, Thangavelu ^c   Naruhashi, Kazumasa ^b   Sugioka, Nobuyuki ^c   Takada, Kanji ^c   Shibata, Nobuhito ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b DOSHISHA WOMEN'S COLLEGE OF LIBERAL ARTS   (Japan)

^c KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CREMOPHOR; CYCLOSPORIN; CYCLOSPORIN A; CYTOCHROME P450 3A4; DIMETHYL SULFOXIDE; GLYCOPROTEIN P; NIFEDIPINE; RHODAMINE 123;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TRANSPORT; ENZYME SUBSTRATE; FLUOROMETRY; INHIBITION KINETICS; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PRIORITY JOURNAL; RAT; TANDEM MASS SPECTROMETRY; TIME; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; BIOLOGICAL TRANSPORT; CALCIUM CHANNEL BLOCKERS; CYCLOSPORINE; DRUG INTERACTIONS; MALE; NIFEDIPINE; P-GLYCOPROTEIN; RATS; RATS, WISTAR; RHODAMINE 123;

EID: 72649106783     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2009.04.031     Document Type: Article

References (38)

1. Lin J.H., Chiba M., and Baillie T.A. Is the role of the small intestine in first-pass metabolism overemphasized?. Pharmacol Rev 51 (1999) 135-157
2. Dresser G.K., Spence D., and Bailey D.G. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharm 38 (2000) 41-57
3. Doherty M.M., and Charman W.N. The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?. Clin Pharm 41 (2002) 235-253
4. Bailey D.G., Spence J.D., Munoz C., and Arnold J.M.O. Interaction of citrus juices with felodipine and nifedipine. Lancet 337 (1991) 268-269
5. Bailey D.G., Arnold J.M.O., and Spence J.D. Grapefruit juice and drugs: how significant is the interaction?. Clin Pharm 26 (1994) 91-98
6. Rashid T.J., Martin U., Clarke H., Waller D.G., Renwick A.G., and George C.F. Factors affecting the absolute bioavailability of nifedipine. Br J Clin Pharmacol 40 (1995) 51-58
7. Wacher V.J., Wu C.Y., and Benet L.Z. Overlapping substrate specificites and tissues distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13 (1995) 129-134
8. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., and Willingham M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci 84 (1987) 7735-7738
9. Sugawara I., Kataoka I., Morishita Y., Hamada H., Tsuruo T., Hoyama S., et al. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res 48 (1988) 1926-1929
10. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., and Willingham M.C. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 37 (1989) 159-164
11. Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci 86 (1989) 695-698
12. Leveque D., and Jehl F. P-glycoprotein and pharmacokinetics. Anticancer Res 15 (1995) 231-336
13. Schinkel A.H., Wagenaar E., van Deemter L., Mol C.A.A.M., and Borst P. Absence of the mdr 1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporine. Am J Clin Invest 96 (1995) 1698-1705
14. Relling M.V. Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs?. Ther Drug Monit 18 (1996) 350-356
15. Tandon V.R., Kapoor B., Bano G., Gupta S., Gillani Z., Gupta S., et al. P-glycoprotein: pharmacological relevance. Ind J Pharmacol 38 (2006) 13-24
16. Hamman J.H., Demana P.H., and Olivier E.I. Targeting receptors, transporters and site of absorption, to improve oral drug delivery. Drug Target Insights 2 (2007) 71-81
17. Tiberghien F., and Loor F. Ranking of P-glycoprotein substrate and inhibitors by a calcein - AM fluorometry screening assay. Anti Cancer Drug 7 (1996) 568-578
18. Ayesh S., Shao Y.M., and Stein W.D. Co-operative, competitive and non-competitive interactions between modulators of P-glycoproteins. Biochim Biophys Acta 1316 (1996) 8-18
19. Scala S., Akhmed N., Rao U.S., Paull K., Lan L.B., Dickstein B., et al. P-glycoprotein substrate and antagonists cluster into two distinct groups. Mol Pharmacol 51 (1997) 1024-1033
20. Mirte M.M., Dick J.R., Jos H.B., Hilde R., Franciska J.K., Wim W.T.B.H., et al. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol 19 4 (2001) 1160-1166
21. Opie L.H., Frishman F.H., and Sica D.A. Cardiovascular drug interactions. In: Frishman F.H., Sonnenblick E.H., and Sica D.A. (Eds). Cardiovascular pharmacotherapeutics manual. 2nd ed. (2004), McGraw-Hill Companies, Inc 464 Chapter 21
22. Nobuhito S., Michiharu K., Keisuke K., Jun T., Hiroto H., Hitomi N., et al. Evaluation of factors to decrease plasma concentration of an HIV protease inhibitor, saquinavir in ethanol-treated rats. Biol Pharm Bull 27 2 (2004) 203-209
23. Sorin E.L., and Laurian V. Pharmacokinetics and metabolic drug interactions. Curr Clin Pharmacol 1 (2006) 5-20
24. Bouër R., Barthe L., Philibert C., Tournaire C., Woodley J., and Houin G. The roles of P-glycoprotein and intracellular metabolism in the intestinal absorption of methadone: in vitro studies using the rat everted intestinal sac. Fundam Clin Pharmacol 13 (1999) 494-500
25. Fromm M.F. Importance of P-glycoprotein at blood-tissue barriers. Trends in Pharmacol Sci 25 8 (2004) 423-429
26. Niwa T., Yamamoto Y., Saito M., Shiraga T., and Takagi A. Effect of cyclosporine and tacrolimus on cytochrome P450 activities in human liver microsomes. Yakugaku Zasshi 127 1 (2007) 209-216
27. Wong S., Wong H.T., and Wacher V.J. Minimal effect of ketoconazole on cyclosporine (SangCyATM) oral absorption and first-pass metabolism in rats: evidence of a significant vehicle effect on sangcya absorption. Biopharm Drug Dispos 23 (2002) 53-57
28. Michiharu K., Hitomi N., Hiroto F., Yukako I., Nobuhito S., and Kanji T. In vivo effects of cyclosporin A and ketaconazole on the pharmacokinetics of representative substrates for P-glycoproteins and cytochrome P450 (CYP) 3A in rats. Biol Pharm Bull 28 2 (2005) 316-322
29. Miki K., Miki N., Hiroshi Y., and Tsuyoshi Y. Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein mediated transport. Eur J Pharm Sci 12 (2001) 505-513
30. Rebbeor J.F., and Senior A.E. Effects of cardiovascular drugs on ATPase activity of P-glycoprotein in plasma membranes and in purified reconstituted form. Biochim Biophys Acta 1369 (1998) 85-93
31. Sun J., He Z., Cheng G., Wang S., Hao X., and Zou M. Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction. Med Sci Monit 10 1 (2004) RA5-RA14
32. Mizuno N., Niwa T., Yotsumoto Y., and Sugiyama Y. Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 55 3 (2003) 425-461
33. Cummins C.L., Salphati L., Reid M.J., and Benet L.Z. In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model. J Pharmacol Exp Ther 305 1 (2003) 306-314
34. Mealey K.L. Therapeutic implications of the MDR-1 gene. J Vet Pharmacol Ther 27 (2004) 257-264
35. Varma M.V.S., Ashokraj Y., Dey C.S., and Panchagnula R. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res 48 (2003) 347-359
36. Williams W.C., and Sinko P.J. Oral absorption of the HIV protease inhibitors: A current update. Adv Drug Deliv Rev 39 (1999) 211-238
37. Chiou W.L., Chung S.M., and Wu T.C. Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice. Pharm Res 17 (2000) 205-208
38. Chiou W.L., Chung S.M., Wu T.C., and Ma C. A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. Int J Clin Pharmacol Ther 39 (2001) 93-101